The FDA found that data from a single Phase II study were “insufficient” to justify an accelerated approval review for ...

Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...

Calico will leverage 9MW3811’s anti-inflammatory mechanism to advance its mission of addressing aging-related diseases.

While ALTO-203 missed its depression-related endpoints, improvements in EEG biomarkers, attention and wakefulness point to ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Minovia’s lead product is MNV-201, an autologous hematopoietic stem cell product that is enriched with allogeneic ...

Susan Monarez, already acting director of the CDC, said during her confirmation hearing that she sees no causal link between ...

Without providing further context, HHS Secretary Robert F. Kennedy Jr. says that Gavi needs to “start taking vaccine safety ...

Writing in JAMA, four former government officials warn that the Trump administration’s involvement in delaying the approval ...

Given today’s available local talent pool, biopharma companies are less likely to turn toward international job candidates, ...

Jefferies analysts called the proxy filing, which is a standard disclosure after a merger agreement, “much more intriguing ...

The FDA is assessing the need for “further regulatory action” on Sarepta's Duchenne muscular dystrophy gene therapy in the ...